Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.
At AMP 2025, a South Korean research team outlined a multimodal approach that integrates CSF, DNA, and MRI data to enable early, noninvasive tumor classification.
At AMP 2025, Takunda Matose, PhD, urged pathologists to consider the limitations of big data and probabilistic reasoning to maximize AI’s benefits for clinical outcomes.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
At AMP’s annual meeting, the organization also honored Alexis Carter, Dara Aisner, and Lawrence Jennings for their contributions to laboratory medicine and molecular pathology.
An analysis of New York State test submissions from 2010 to 2024, presented at AMP 2025, shows steady growth of NGS panels, WES, WGS, and cfDNA testing.
In her keynote lecture, Elaine R. Mardis, PhD, discussed advances in pediatric precision medicine and encouraged the expansion of data-sharing initiatives.